Arunalight and Wet AMD

Arunalight for Wet AMD

Clinical Safety & Use Statement – Patients Receiving Anti-VEGF Therapy

Arunalight® photobiomodulation (PBM) is not intended to treat neovascular (wet) age-related macular degeneration and does not replace anti-VEGF therapy. Anti-VEGF injections remain the standard of care and should be continued without delay or modification.

Clinical PBM trials, including LIGHTSITE III, evaluated PBM in non-neovascular (dry) AMD populations. PBM has not been established as a treatment for choroidal neovascularization, nor as an adjunct that alters anti-VEGF dosing requirements or outcomes.

There is currently no clinical evidence demonstrating that PBM interferes with anti-VEGF pharmacodynamics or increases injection-related adverse events. However, prospective safety data in eyes actively receiving anti-VEGF therapy are limited, and PBM use in this population should be considered supportive and discretionary.

If PBM is used in patients receiving injections, the following precautions are recommended:

• Arunalight® use in patients with active neovascular AMD should be under the supervision of a retinal specialist

• PBM should not be administered on injection days

• PBM sessions should be temporally separated from injections

• PBM should be discontinued if new exudative changes, hemorrhage, or unexplained visual decline occurs

• Ongoing retinal monitoring remains essential